Valiant Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Valiant Laboratories reported strong standalone performance for FY2026 with revenue from operations growing 63% to ₹21,704.25 lakhs from ₹13,336.18 lakhs in the prior year. The company swung from a standalone net loss of ₹215.02 lakhs in FY2025 to a net profit of ₹554.82 lakhs in FY2026. However, on a consolidated basis (which includes subsidiary Valiant Advanced Sciences Private Limited), the group posted a net loss of ₹326.79 lakhs versus a loss of ₹220.12 lakhs previously, due to significantly higher finance costs (₹190.25 lakhs vs ₹17.53 lakhs) and depreciation (₹603.98 lakhs vs ₹209.26 lakhs) at the subsidiary level. The auditors (Raman S. Shah & Co.) issued an un-modified (clean) opinion on both standalone and consolidated results.
Standalone results are positive showing a profit turnaround and strong revenue growth. However, the consolidated net loss despite higher group revenue signals that the subsidiary is still not profitable and is increasing group-level debt and depreciation costs, which could concern investors.